Friday, October 12, 2012
Recipharm, a Swedish contract development and manufacturing organization, and Astimex Pharma, a Swedish pharmaceutical company, have formed a collaboration agreement for the development and manufacture of a pharmaceutical product.
The formulation development work will take place at the Recipharm Pharmaceutical Development site located in Solna, close to Stockholm. Astimex Pharma also has the opportunity to choose Recipharm as the future manufacturer for the product.
Additionally, Astimex is in discussions with Recipharm for engagement to carry out other manufacturing and development contractual projects.
“I am convinced that this is the start of a long-term collaboration that will prove beneficial for both companies and we are pleased that Astimex Pharma has chosen to utilize the expertise and flexible development capabilities that our staff and facilities are able to provide,” said Maria Lundberg, general manager, Recipharm Pharmaceutical Development.
“It is Recipharm’s recognized partnering approach, combined with its advanced and adaptable capabilities, including its offering at the Solna facility, that attracted us in the first place,” said Åsa Lintzen, general manager, Astimex Pharma. “Moreover, we were looking for a CDMO that we could build a long term relationship with and consequently we are already exploring the scope for working with Recipharm on other projects.”